Sedulo Group — Recent Moves (14 tracked, last 90 days)

Sedulo Group is a competitive-intelligence and strategic-research firm whose recent activity, as captured in 14 tracked moves, shows a company building out a portfolio of frameworks, assessment tools, and conference presence aimed squarely at life-sciences and B2B commercial teams. Its output spans sales intelligence, counterintelligence auditing, wargaming, deal-desk design, and pharma marketing positioning — a breadth that suggests it is positioning itself less as a one-off research vendor and more as a repeatable methodology provider.

Watching Sedulo Group right now matters because its moves cluster tightly around the 2026 conference calendar and around productised tools rather than bespoke engagements. That shift — from selling studies to selling frameworks, maturity assessments, and surveys — is the kind of change that reshapes how a firm competes for budget against both consultancies and benchmarking-report publishers.

Productisation of methodology: Sedulo Group has been converting its know-how into named, reusable assets. In mid-August 2026 it launched a Strategic Intelligence Maturity Assessment Tool, and in late July it launched a Framework for B2B Deal Desk Implementation. Earlier, in late June, it was positioning custom research against generic benchmarking reports, and by late August it was featuring sales-intelligence and CRM-limitation content. The pattern is a firm moving from selling hours and reports toward selling structured instruments that clients can adopt repeatedly — a margin and scalability play, and a signal that Sedulo Group wants to be embedded in client process rather than consulted episodically.

Life-sciences and pharma concentration: A large share of recent moves point at pharma and life sciences specifically. Sedulo Group announced a performance presentation for Pharma CI Europe 2026 and became lead sponsor for Pharma CI USA 2026 in late July, opened its 2026 Life Sciences Competitive Intelligence Survey in late July, and published a pharma BD scouting case study in mid-July. It also released a pharma marketing positioning framework for crowded markets in early July. This is a deliberate vertical bet: Sedulo Group is buying visibility and thought-leadership position inside the pharma CI community, where conference sponsorship and survey ownership are the standard routes to pipeline.

Defensive and adversarial intelligence framing: Sedulo Group is increasingly framing its offer around defence and counter-moves rather than pure market description. In mid-August it positioned counterintelligence auditing for defensive strategy, and in early August it made strategic wargaming and market landscape assets available. Combined with the cybersecurity and diagnostics D2C case studies released in late July, this suggests Sedulo Group is courting buyers who need to protect position and anticipate competitor action — a higher-stakes, higher-value conversation than generic market sizing.

Demand generation through owned media and data: Sedulo Group is running a content-and-community engine alongside its services. It is promoting "The Intelligence Exchange" newsletter for executive decision support (late June), running the life-sciences CI survey, and deploying real-time oncology sales monitoring and HRM GTM case studies (late June). Owning a survey and a newsletter gives Sedulo Group first-party data and a recurring touchpoint with exactly the executives it wants to sell frameworks and assessments to.

What to watch: Track whether the maturity assessment tool and deal-desk framework get packaged into recurring subscription or licence revenue, since that would mark a genuine business-model shift rather than a marketing refresh. Also watch whether the pharma conference sponsorships convert into named case studies or survey-driven benchmark products, which would show Sedulo Group monetising its community position. Finally, monitor whether the counterintelligence and wargaming positioning pulls it upmarket into larger enterprise engagements.